Tumor cells inhibit the activation of ILC2s through up-regulating PD-1 expression.

Autor:	Yin C; Department of Emergency Medicine, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin, P. R. China.; Department of General Surgery, The Affiliated Hospital of Jiangsu University, Zhenjiang, P. R. China., Pa Y; Department of General Surgery, The Affiliated Hospital of Jiangsu University, Zhenjiang, P. R. China., Li G; Department of General Surgery, The Affiliated Hospital of Jiangsu University, Zhenjiang, P. R. China., Chen Q; Department of Emergency Medicine, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin, P. R. China., Wang X; Department of General Surgery, The Affiliated Hospital of Jiangsu University, Zhenjiang, P. R. China., He X; Department of Emergency Medicine, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin, P. R. China., Zhou H; Department of Emergency Medicine, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin, P. R. China.
Jazyk:	angličtina
Zdroj:	Immunopharmacology and immunotoxicology [Immunopharmacol Immunotoxicol] 2024 Jun; Vol. 46 (3), pp. 417-423. Date of Electronic Publication: 2024 May 14.
DOI:	10.1080/08923973.2024.2347315
Abstrakt:	Objective: Up-regulating programmed cell death ligand-1(PD-L1) expressed on tumor cells and tumor-infiltrating myeloid cells interacting with up-regulated programmed cell death-1 (PD-1) expressed on tumor-infiltrating lymphoid cells greatly hinder their tumor-inhibiting effect. It is necessary to explore the deep mechanism of this negative effect, so as to find the potential methods to improve the immunotherapy efficiency. Methods and Results: In this study, we found that the PD-1 expression in lung cancer-infiltrating type II innate lymphoid cells (ILC2s) was highly up-regulated, which greatly restrained the activation and function of ILC2s. Furthermore, anti-PD-1 could restore the inhibition and effective cytokine secretion of ILC2s when co-cultured with tumor cells. In vivo studies proved that anti-PD-1 treatment promoted the activation of tumor-infiltrating ILC2s and inhibited the tumor growth of LLC-bearing nude mice. Discussion: Our studies demonstrate a new PD-1/PD-L1 axis regulating mechanism on innate immune cells, which provide a useful direction to ILC2s-based immunotherapy to cancer diseases.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu